Study to Evaluate DNL151 in Subjects With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

December 2, 2020

Study Completion Date

December 2, 2020

Conditions
Parkinson's Disease
Interventions
DRUG

DNL151

Oral repeating dose

DRUG

Placebo

Oral repeating dose

Trial Locations (8)

2333

Centre for Human Drug Research, Leiden

3000

UZ Leuven, Leuven

32806

PPD Clinical Research Unit, Orlando

48334

Quest Research Institute, Farmington Hills

8934AD

QPS, Leeuwarden

L7 8XP

Royal Liverpool University Hospital, Liverpool

M13 9NQ

MAC Clinical Research, Manchester

CF48 4DR

Simbec-Orion Clinical Pharmacology, Merthyr Tydfil

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY